Status:
COMPLETED
Neoadjuvant Endocrine Therapy in Breast Cancer
Lead Sponsor:
Guangdong Provincial People's Hospital
Conditions:
Highly Endocrine Responsive Operable Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and ...
Detailed Description
Estrogen receptor (ER) positive constitutes about 75% of all breast cancer(BC). Neoadjuvant endocrine therapy(NET) plays an important part in primary therapy of the hormone receptor (HR) -positive and...
Eligibility Criteria
Inclusion
- Females ≥18 years
- ER-positive (≥50%), PgR-positive (≥50% ), HER2-negative, and previously untreated, non-metastatic primary invasive BC.
- The tumour size had to be \>1 cm.
Exclusion
- male patients;
- patients with inflammatory breast cancer or distant metastasis;
- patients who were previously treatment treated with chemotherapy, radiation therapy or prior treatment with AIs or antiestrogens for breast cancer;
- patients with a second concomitant neoplasm;
- patients who could not meet the eligibility criteria.
Key Trial Info
Start Date :
September 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03397537
Start Date
September 1 2012
End Date
July 1 2017
Last Update
January 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minyi Cheng
Guanzhou, Guangdong, China, 510080